

Resource Summary Report

Generated by [RRID](#) on Aug 12, 2026

OLINDA/EXM

RRID:SCR_026835

Type: Tool

Proper Citation

OLINDA/EXM (RRID:SCR_026835)

Resource Information

URL: <https://jnm.snmjournals.org/content/46/6/1023.long>

Proper Citation: OLINDA/EXM (RRID:SCR_026835)

Description: Software to evaluate mean absorbed doses to organs and tumors in radionuclide images, providing simple and fast solution for radionuclide imaging and treatment of new drugs in clinical trials. Calculates radiation doses to organs and the whole body based on established human body models.

Synonyms: , Organ Level Internal Dose Assessment/EXponential Modeling, OLINDA/EXM 2, Hermes Medical Solutions OLINDA/EXM

Resource Type: software application, software resource

Defining Citation: [PMID:15937315](#), [PMID:36780284](#)

Keywords: Calculate radiation doses, evaluate mean absorbed doses to organs and tumors, radionuclide images, clinical trials,

Availability: Restricted

Resource Name: OLINDA/EXM

Resource ID: SCR_026835

Record Creation Time: 20250424T064808+0000

Record Last Update: 20260810T040920+0000

Ratings and Alerts

No rating or validation information has been found for OLINDA/EXM.

No alerts have been found for OLINDA/EXM.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Young AJ, et al. (2026) First-in-Human Biodistribution and Dosimetry of [11C]Trimethoprim. *Molecular imaging and biology*, 28(1), 60.

Pattanawong O, et al. (2026) Post-Therapeutic Dosimetry of Metastatic Castration-Resistant Prostate Cancer With 177Lu-PSMA: Experiences From Two University-Based Hospitals in Thailand. *Asia-Pacific journal of clinical oncology*, 22(2), 199.

Longo M, et al. (2026) Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms. *EJNMMI research*, 16(1).

Herrmann K, et al. (2024) Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*, 65(1), 71.

Li M, et al. (2024) Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy. *European journal of nuclear medicine and molecular imaging*, 51(5), 1395.

Hansen AR, et al. (2024) Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. *Frontiers in oncology*, 14, 1483953.

Brooks AF, et al. (2022) Development of Fluorinated NP-59: A Revival of Cholesterol Use Imaging with PET. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*, 63(12), 1949.

Huizing DMV, et al. (2020) A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. *EJNMMI physics*, 7(1), 36.

Dubash SR, et al. (2020) Clinical translation of 18F-fluoropivalate - a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers. *European journal of nuclear medicine and molecular imaging*, 47(11), 2549.

Lisova K, et al. (2018) Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. *Nuclear medicine and biology*, 61, 36.

Yoshii Y, et al. (2018) Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with ^{64}Cu -labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts. *Oncotarget*, 9(48), 28935.

Shidahara M, et al. (2013) Evaluation of the biodistribution and radiation dosimetry of the ^{18}F -labelled amyloid imaging probe ^{18}F FACT in humans. *EJNMMI research*, 3(1), 32.